|Bid||3.20 x 1800|
|Ask||4.26 x 100|
|Day's Range||3.3100 - 3.5200|
|52 Week Range||3.1000 - 6.7000|
|Beta (3Y Monthly)||2.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Harvard Bioscience Inc (NASDAQ:HBIO) is a small-cap stock with a market capitalization of US$139m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...
HOLLISTON, Mass., Nov. 02, 2018 -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science,.
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 0.75%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Holliston, Massachusetts-based company said it had a loss of 1 cent. Earnings, adjusted for amortization costs and stock option expense, came to 4 cents per share. The medical ...
-Reports GAAP and adjusted non-GAAP revenue of $28.6 million and $28.7 million, respectively, an increase of 53% and 15%, respectively- HOLLISTON, Mass., Oct. 25, 2018 --.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit 52-week highs in Monday's session. Down In The Dumps (Biotech stocks hitting 52-week ...
Ms. Unninayar joins Harvard Bioscience with global financial leadership experience spanning more than two decades at public companies in the life sciences and consumer product industries. Ms. Unninayar spent more than eleven years at Thermo Fisher Scientific, a global leader in serving science, across multiple roles leading financial operations, corporate financial planning and analysis, finance for business strategy, and acquisitions and integrations. Earlier in her career, Ms. Unninayar held finance roles with increasing responsibilities at Fortune 500 consumer companies.
Harvard Bioscience, Inc. (HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2018 after market trading hours on Thursday, October 25, 2018.
If you own shares in Harvard Bioscience Inc (NASDAQ:HBIO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
The Zacks Analyst Blog Highlights: BG, Harvard Bioscience, Vertex Energy, Hallmark and Summer Infant
Penny stocks approaching key price levels dominate September's technical analysis buy list, telling interested traders to build watch lists and track progress while awaiting fruitful buying signals or reversals that break bullish patterns. First, establish the price level that is likely to attract strong buying interest. Second, look for the price level that is likely to attract strong selling interest.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 26) ADMA Biologics Inc (NASDAQ: ADMA )(announced it has addressed ...
Harvard Bioscience Inc (NASDAQ:HBIO), a life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM.Read More...